A. Catchpole

发表

A Throat Lozenge Containing Amyl Meta Cresol and Dichlorobenzyl Alcohol Has a Direct Virucidal Effect on Respiratory Syncytial Virus, Influenza a and SARS-CoV

J. Oxford, S. Balasingam, R. Lambkin, 2005, Antiviral chemistry & chemotherapy.

The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic

H. Johnson, P. Pristerà, Emma Smith, 2022, Epidemics.

A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report.

G. Kang, S. Bull, M. Parker, 2020, Biologicals : journal of the International Association of Biological Standardization.

Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge

J. Oxford, Rob Lambkin-Williams, A. Mann, 2014, PloS one.

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

A. Mann, P. Dormitzer, A. Gurtman, 2022, The New England journal of medicine.

Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM).

Rob Lambkin-Williams, C. Laxton, N. Noulin, 2015, Journal of virological methods.

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

A. Mann, N. Ferguson, C. Hopkins, 2022, Nature Medicine.

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

A. Mann, N. Ferguson, C. Hopkins, 2022 .

Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene.

E. Fodor, G. Brownlee, L. Mingay, 2003, The Journal of general virology.

The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2018, Respiratory Research.

SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic.

H. McShane, Emma Smith, Garth William Rapeport, 2021, The New England journal of medicine.

New Antiviral Drugs, Vaccines and Classic Public Health Interventions against SARS Coronavirus

J. Oxford, S. Balasingam, R. Lambkin, 2005, Antiviral chemistry & chemotherapy.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2018, BMC Research Notes.

Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study

A. Mann, Jie Zhou, N. Ferguson, 2023, The Lancet Microbe.

SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections.

A. Mann, B. Chain, M. Kaforou, 2023, medRxiv.

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Daniel S Spellman, Amy S. Espeseth, A. Espeseth, 2021, EBioMedicine.

Mucosal and Systemic Immune Correlates of Viral Control following SARS-CoV-2 Infection Challenge in Seronegative Adults

M. Davenport, B. Chain, Mann, 2023, medRxiv.

Human SARS-CoV-2 challenge resolves local and systemic response dynamics

A. Mann, E. Prigmore, R. Chambers, 2023, medRxiv.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Andrew P. Catchpole, Daniel J. Fullen, Nicolas Noulin, 2018, BMC Research Notes.

Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults

R. Thwaites, B. Killingley, A. Reynaldi, 2024, Science Immunology.

Lack of association between HLA and asymptomatic SARS-CoV-2 infection

J. Fellay, S. Tangye, Shen-Ying Zhang, 2023, medRxiv.